GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio, Inc. (FRA:YFK) » Definitions » COGS-to-Revenue

3SBio, (FRA:YFK) COGS-to-Revenue : 0.15 (As of Dec. 2016)


View and export this data going back to . Start your Free Trial

What is 3SBio, COGS-to-Revenue?

3SBio,'s Cost of Goods Sold for the six months ended in Dec. 2016 was €31.6 Mil. Its Revenue for the six months ended in Dec. 2016 was €204.5 Mil.

3SBio,'s COGS to Revenue for the six months ended in Dec. 2016 was 0.15.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. 3SBio,'s Gross Margin % for the six months ended in Dec. 2016 was 84.55%.


3SBio, COGS-to-Revenue Historical Data

The historical data trend for 3SBio,'s COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio, COGS-to-Revenue Chart

3SBio, Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec14 Dec15 Dec16
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.11 0.08 0.14 0.14

3SBio, Semi-Annual Data
Jun06 Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.13 0.16 0.13 0.15

3SBio, COGS-to-Revenue Calculation

3SBio,'s COGS to Revenue for the fiscal year that ended in Dec. 2016 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=55.109 / 383.223
=0.14

3SBio,'s COGS to Revenue for the quarter that ended in Dec. 2016 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=31.589 / 204.459
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3SBio,  (FRA:YFK) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

3SBio,'s Gross Margin % for the six months ended in Dec. 2016 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 31.589 / 204.459
=84.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


3SBio, COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of 3SBio,'s COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio, (FRA:YFK) Business Description

Traded in Other Exchanges
N/A
Address
3SBio Inc is engaged in the healthcare sector based in China. It is a pharmaceutical products company and its core activities pertain to developing, manufacturing and marketing biopharmaceuticals. Its portfolio of products comprises of TPIAO and Yisaipu. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world and Yisaipu is a TNF inhibibator product and accounts for the major share in the pharmaceutical industry in China. Most of the company's activities are focused on China while having a minor footprint in a foreign land.

3SBio, (FRA:YFK) Headlines

No Headlines